Brigatinib is manufactured by Takeda Pharmaceutical Company [1].
Who makes Brigatinib?
Takeda Pharmaceutical Company is the manufacturer of brigatinib [1].
What is brigatinib used for?
Brigatinib is a prescription medication used to treat adults with anaplastic lymphoma kinase-positive (ALK-positive) metastatic non-small cell lung cancer (NSCLC) [2]. It is typically prescribed for patients whose disease has worsened during or after treatment with another ALK inhibitor [2].
When does brigatinib's patent expire?
Information on brigatinib's patent expiry is available through DrugPatentWatch.com [3].
What are the alternatives to brigatinib for ALK-positive NSCLC?
Other ALK inhibitors used for ALK-positive metastatic NSCLC include crizotinib, ceritinib, alectinib, and lorlatinib [4]. The choice of treatment depends on factors such as the patient's specific mutation profile, prior treatments, and physician recommendation [4].
How is brigatinib administered?
Brigatinib is taken orally, usually once a day, with or without food [2]. The dosage and duration of treatment are determined by a healthcare professional [2].
What are the potential side effects of brigatinib?
Common side effects of brigatinib can include diarrhea, nausea, fatigue, cough, increased blood pressure, and rash [2]. More serious side effects can occur, such as lung problems, heart problems, and vision changes [2]. Patients should discuss any concerns about side effects with their doctor [2].
Sources:
[1] https://www.drugs.com/brigatinib.html
[2] https://www.cancer.gov/rare-brain-spine-tumors/drug/FDA/brigatinib
[3] https://www.drugpatentwatch.com/
[4] https://www.cancer.org/cancer/types/non-small-cell-lung-cancer/treatment/targeted-therapy.html